ADAM23 and astrocytoma (excluding glioblastoma): Our discoveries suggest that ADAM23 downregulation in astrocytoma cells activates GS promoting the proneural-mesenchymal transition (PMT) and providing an experimental basis for the use of GSI for astrocytoma patients with ADAM23low tumors.